IDEXX Laboratories, Inc. (IDXX) EV/EBIT Ratio: 32.96x
Is IDEXX Laboratories, Inc.’s EV/EBIT ratio high or low?
IDEXX Laboratories, Inc.'s EV/EBIT ratio of 32.96x is 23% below its 5-year average of 42.83x, near the low end of its 5-year range (27.03x–77.53x).
The EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX) is 32.96x as of Wednesday, June 10, 2026. It is below its 12-month average by 17.12% (39.77x).
IDXX EV/EBIT Ratio Chart
IDXX Average EV/EBIT Ratio Chart
IDXX Current vs Average EV/EBIT Ratio Chart
IDXX EV/EBIT Ratio Metrics
EV/EBIT RATIO
32.96x
EV/EBIT RATIO AVG TTM
39.77x
EV/EBIT RATIO AVG 3Y
38.49x
EV/EBIT RATIO AVG 5Y
42.83x
EV/EBIT RATIO AVG 10Y
44.40x
EV/EBIT RATIO AVG 15Y
37.47x
EV/EBIT RATIO AVG 20Y
33.30x
CURRENT VS TTM AVG
-17.12%
CURRENT VS 3Y AVG
-14.37%
CURRENT VS 5Y AVG
-23.05%
CURRENT VS 10Y AVG
-25.76%
CURRENT VS 15Y AVG
-12.05%
CURRENT VS 20Y AVG
-1.01%
IDXX Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 32.96x | 39.77x | 38.49x | 42.83x |
| Humana Inc. (HUM) | $43.78B | 38.35x | 22.15x | 19.20x | 18.80x |
| Agilent Technologies, Inc. (A) | $37.17B | 25.03x | 26.26x | 27.12x | 28.92x |
| Zoetis Inc. (ZTS) | $34.20B | 11.68x | 17.91x | 24.03x | 27.39x |
| Centene Corporation (CNC) | $31.94B | N/A | 10.37x | 16.91x | 20.65x |
| Medline Inc. (MDLN) | $30.90B | 19.75x | 21.22x | 21.22x | 21.22x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 13.56x | 20.40x | 24.04x | 30.04x |
| DexCom, Inc. (DXCM) | $29.24B | 29.06x | 38.74x | 65.30x | 101.94x |
| Biogen Inc. (BIIB) | $29.00B | 20.98x | 13.26x | 14.80x | 15.73x |
| Veeva Systems Inc. (VEEV) | $26.73B | 26.56x | 45.54x | 60.66x | 66.33x |
IDEXX Laboratories, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The EV/EBIT ratio for IDXX stock is 32.96x.
- Is IDEXX Laboratories, Inc.'s EV/EBIT ratio high or low?
- IDEXX Laboratories, Inc.'s EV/EBIT ratio of 32.96x is 23% below its 5-year average of 42.83x, near the low end of its 5-year range (27.03x–77.53x).
- What is the TTM average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average EV/EBIT ratio for IDXX stock is 39.77x.
- What is the 3Y average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average EV/EBIT ratio for IDXX stock is 38.49x.
- What is the 5Y average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average EV/EBIT ratio for IDXX stock is 42.83x.
- What is the 10Y average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average EV/EBIT ratio for IDXX stock is 44.40x.
- What is the 15Y average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average EV/EBIT ratio for IDXX stock is 37.47x.
- What is the 20Y average EV/EBIT ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average EV/EBIT ratio for IDXX stock is 33.30x.
IDEXX Laboratories, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-10 | 32.96x |
| 2026-06-09 | 33.84x |
| 2026-06-08 | 32.82x |
| 2026-06-05 | 32.88x |
| 2026-06-04 | 33.03x |
| 2026-06-03 | 32.80x |
| 2026-06-02 | 32.23x |
| 2026-06-01 | 33.14x |
| 2026-05-29 | 32.96x |
| 2026-05-28 | 33.22x |
| 2026-05-27 | 32.24x |
| 2026-05-26 | 32.59x |
| 2026-05-22 | 32.72x |
| 2026-05-21 | 32.36x |
| 2026-05-20 | 32.39x |
| 2026-05-19 | 31.98x |
| 2026-05-18 | 31.94x |
| 2026-05-15 | 30.96x |
| 2026-05-14 | 31.20x |
| 2026-05-13 | 30.96x |
| 2026-05-12 | 31.26x |
| 2026-05-11 | 31.15x |
| 2026-05-08 | 32.76x |
| 2026-05-07 | 33.45x |
| 2026-05-06 | 33.86x |
| 2026-05-05 | 32.93x |
| 2026-05-04 | 34.06x |
| 2026-05-01 | 34.32x |
| 2026-04-30 | 33.93x |
| 2026-04-29 | 33.50x |
| 2026-04-28 | 34.37x |
| 2026-04-27 | 34.76x |
| 2026-04-24 | 34.23x |
| 2026-04-23 | 33.93x |
| 2026-04-22 | 34.97x |
| 2026-04-21 | 34.41x |
| 2026-04-20 | 35.25x |
| 2026-04-17 | 35.61x |
| 2026-04-16 | 34.47x |
| 2026-04-15 | 35.11x |
| 2026-04-14 | 35.30x |
| 2026-04-13 | 34.71x |
| 2026-04-10 | 34.06x |
| 2026-04-09 | 35.35x |
| 2026-04-08 | 35.77x |
| 2026-04-07 | 34.76x |
| 2026-04-06 | 34.91x |
| 2026-04-02 | 34.44x |
| 2026-04-01 | 34.15x |
| 2026-03-31 | 33.99x |
| 2026-03-30 | 33.71x |
| 2026-03-27 | 33.78x |
| 2026-03-26 | 34.67x |
| 2026-03-25 | 34.81x |
| 2026-03-24 | 34.48x |
| 2026-03-23 | 34.98x |
| 2026-03-20 | 34.90x |
| 2026-03-19 | 35.06x |
| 2026-03-18 | 34.89x |
| 2026-03-17 | 35.48x |
| 2026-03-16 | 35.44x |
| 2026-03-13 | 34.70x |
| 2026-03-12 | 34.54x |
| 2026-03-11 | 36.28x |
| 2026-03-10 | 36.18x |
| 2026-03-09 | 36.87x |
| 2026-03-06 | 36.75x |
| 2026-03-05 | 37.37x |
| 2026-03-04 | 39.14x |
| 2026-03-03 | 38.36x |
| 2026-03-02 | 38.43x |
| 2026-02-27 | 39.62x |
| 2026-02-26 | 39.85x |
| 2026-02-25 | 39.65x |
| 2026-02-24 | 39.17x |
| 2026-02-23 | 37.62x |
| 2026-02-20 | 38.37x |
| 2026-02-19 | 39.65x |
| 2026-02-18 | 39.91x |
| 2026-02-17 | 39.37x |
| 2026-02-13 | 39.57x |
| 2026-02-12 | 38.82x |
| 2026-02-11 | 40.76x |
| 2026-02-10 | 40.63x |
| 2026-02-09 | 40.21x |
| 2026-02-06 | 40.51x |
| 2026-02-05 | 40.45x |
| 2026-02-04 | 40.41x |
| 2026-02-03 | 39.76x |
| 2026-02-02 | 40.20x |
| 2026-01-30 | 42.11x |
| 2026-01-29 | 42.49x |
| 2026-01-28 | 43.17x |
| 2026-01-27 | 43.61x |
| 2026-01-26 | 43.80x |
| 2026-01-23 | 43.55x |
| 2026-01-22 | 43.38x |
| 2026-01-21 | 43.71x |
| 2026-01-20 | 43.07x |
| 2026-01-16 | 44.88x |
| 2026-01-15 | 44.68x |
| 2026-01-14 | 44.58x |
| 2026-01-13 | 44.80x |
| 2026-01-12 | 45.46x |
| 2026-01-09 | 44.75x |
| 2026-01-08 | 44.70x |
| 2026-01-07 | 44.83x |
| 2026-01-06 | 44.35x |
| 2026-01-05 | 42.83x |
| 2026-01-02 | 42.08x |
| 2025-12-31 | 42.48x |
| 2025-12-30 | 42.84x |
| 2025-12-29 | 43.18x |
| 2025-12-26 | 43.22x |
| 2025-12-24 | 43.20x |
| 2025-12-23 | 42.84x |
| 2025-12-22 | 44.06x |
| 2025-12-19 | 43.95x |
| 2025-12-18 | 43.75x |
| 2025-12-17 | 43.66x |
| 2025-12-16 | 43.51x |
| 2025-12-15 | 43.96x |
| 2025-12-12 | 44.19x |
| 2025-12-11 | 44.39x |
| 2025-12-10 | 44.04x |
| 2025-12-09 | 43.87x |
| 2025-12-08 | 44.34x |
| 2025-12-05 | 44.80x |
| 2025-12-04 | 45.01x |
| 2025-12-03 | 45.53x |
| 2025-12-02 | 45.95x |
| 2025-12-01 | 45.72x |
| 2025-11-28 | 47.20x |
| 2025-11-26 | 47.39x |
| 2025-11-25 | 48.05x |
| 2025-11-24 | 47.15x |
| 2025-11-21 | 45.53x |
| 2025-11-20 | 43.27x |
| 2025-11-19 | 43.75x |
| 2025-11-18 | 42.09x |
| 2025-11-17 | 42.02x |
| 2025-11-14 | 43.31x |
| 2025-11-13 | 44.02x |
| 2025-11-12 | 44.77x |
| 2025-11-11 | 44.70x |
| 2025-11-10 | 44.52x |
| 2025-11-07 | 44.45x |
| 2025-11-06 | 44.78x |
| 2025-11-05 | 45.18x |
| 2025-11-04 | 45.30x |
| 2025-11-03 | 45.35x |
| 2025-10-31 | 41.48x |
| 2025-10-30 | 41.41x |
| 2025-10-29 | 41.36x |
| 2025-10-28 | 41.79x |
| 2025-10-27 | 42.63x |
| 2025-10-24 | 42.21x |
| 2025-10-23 | 42.06x |
| 2025-10-22 | 41.75x |
| 2025-10-21 | 41.97x |
| 2025-10-20 | 42.37x |
| 2025-10-17 | 41.86x |
| 2025-10-16 | 41.98x |
| 2025-10-15 | 42.10x |
| 2025-10-14 | 41.95x |
| 2025-10-13 | 41.72x |
| 2025-10-10 | 40.61x |
| 2025-10-09 | 41.43x |
| 2025-10-08 | 41.50x |
| 2025-10-07 | 41.33x |
| 2025-10-06 | 41.36x |
| 2025-10-03 | 41.58x |
| 2025-10-02 | 41.76x |
| 2025-10-01 | 40.87x |
| 2025-09-30 | 42.08x |
| 2025-09-29 | 41.54x |
| 2025-09-26 | 41.65x |
| 2025-09-25 | 40.74x |
| 2025-09-24 | 41.33x |
| 2025-09-23 | 42.69x |
| 2025-09-22 | 42.42x |
| 2025-09-19 | 43.20x |
| 2025-09-18 | 43.15x |
| 2025-09-17 | 42.21x |
| 2025-09-16 | 42.52x |
| 2025-09-15 | 42.41x |
| 2025-09-12 | 42.23x |
| 2025-09-11 | 42.49x |
| 2025-09-10 | 42.02x |
| 2025-09-09 | 43.16x |
| 2025-09-08 | 42.98x |
| 2025-09-05 | 42.35x |
| 2025-09-04 | 42.18x |
| 2025-09-03 | 41.76x |
| 2025-09-02 | 42.12x |
| 2025-08-29 | 42.61x |
| 2025-08-28 | 42.61x |
| 2025-08-27 | 42.21x |
| 2025-08-26 | 42.26x |
| 2025-08-25 | 42.24x |
| 2025-08-22 | 42.51x |
| 2025-08-21 | 41.70x |
| 2025-08-20 | 42.14x |
| 2025-08-19 | 41.94x |
| 2025-08-18 | 42.02x |
| 2025-08-15 | 42.85x |
| 2025-08-14 | 43.05x |
| 2025-08-13 | 43.70x |
| 2025-08-12 | 42.94x |
| 2025-08-11 | 42.93x |
| 2025-08-08 | 43.32x |
| 2025-08-07 | 42.80x |
| 2025-08-06 | 41.13x |
| 2025-08-05 | 42.28x |
| 2025-08-04 | 44.91x |
| 2025-08-01 | 39.07x |
| 2025-07-31 | 38.98x |
| 2025-07-30 | 41.68x |
| 2025-07-29 | 41.75x |
| 2025-07-28 | 41.28x |
| 2025-07-25 | 41.19x |
| 2025-07-24 | 40.10x |
| 2025-07-23 | 39.43x |
| 2025-07-22 | 38.81x |
| 2025-07-21 | 38.02x |
| 2025-07-18 | 37.57x |
| 2025-07-17 | 37.86x |
| 2025-07-16 | 38.00x |
| 2025-07-15 | 38.43x |
| 2025-07-14 | 38.77x |
| 2025-07-11 | 38.91x |
| 2025-07-10 | 39.46x |
| 2025-07-09 | 39.43x |
| 2025-07-08 | 39.30x |
| 2025-07-07 | 39.78x |
| 2025-07-03 | 39.89x |
| 2025-07-02 | 39.58x |
| 2025-07-01 | 39.58x |
| 2025-06-30 | 39.12x |
| 2025-06-27 | 38.77x |
| 2025-06-26 | 38.51x |
| 2025-06-25 | 38.70x |
| 2025-06-24 | 38.71x |
| 2025-06-23 | 38.29x |
| 2025-06-20 | 38.24x |
| 2025-06-18 | 37.95x |
| 2025-06-17 | 38.00x |
| 2025-06-16 | 38.58x |
| 2025-06-13 | 38.15x |
| 2025-06-12 | 38.45x |
| 2025-06-11 | 38.26x |
| 2025-06-10 | 38.38x |
| 2025-06-09 | 37.86x |
| 2025-06-06 | 38.31x |
| 2025-06-05 | 38.11x |
| 2025-06-04 | 38.30x |
| 2025-06-03 | 38.37x |
| 2025-06-02 | 37.58x |
| 2025-05-30 | 37.48x |
| 2025-05-29 | 37.64x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky